{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2013"],"data_sharing_plan":["IPD Sharing (as of September 2016): No"],"condition":["DMBT1 Protein, Human","Colorectal Cancer","Colorectal Neoplasms"],"disease":["Colorectal Cancer","Colorectal Neoplasms","Dmbt1 Protein, Human"],"study_type":["Observational"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2225068"],"study_start_month":["6"],"keyword":["DMBT1 expression"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Expression of DMBT1 in Colorectal Cancer Patients","description":"Although colorectal cancer is a preventable and curable disease if early stage tumors are removed, it is still the fourth cause of cancer worldwide and the second leading cause of death in many industrialized countries. The 5-year survival is about 55% often due to a late detection. Then, the identification of sensitive and specific molecular markers is therefore a major challenge for early diagnosis and prognosis of this disease.\nPreliminary work have reported variations in the expression of DMBT1 (deleted in malignant brain tumor 1), a glycoprotein co-secreted with mucins in the light of the glands, during several stages of colon carcinogenesis. The goal of this study is to study by mass spectrometry (MS), alterations in the repertoire of glycosylation of mucins from colorectal tumors of various stages, grades, and recurrence status.","dates":{"creation":"2013-06-15"},"accession":"2225068","cross_references":{"ClinicalTrials___gov":["NCT02901600"]}}